These observations indicated that the clinical association of PPI administration with therapeutic outcomes would be larger in patients with NSCLC with a PD-L1 TPS of 50% or more undergoing ICI monotherapy than in those receiving ICI plus chemotherapy regimens. The gene discussed is CD274; the disease is non-small cell lung carcinoma.